Cargando…

Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol

AIM: To show the characteristics and outcomes of patients with neovascular age-related macular degeneration (nAMD) who had extended remission (ER) while on a pro re nata (PRN) treatment protocol. METHODS: This was a retrospective case–control study of a consecutive series of patients with nAMD treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Tiezhu, Dans, Kunny C, Muftuoglu, Ilkay Kilic, Meshi, Amit, Amador-Patarroyo, Manuel J, Cheng, Lingyun, Freeman, William R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6922015/ https://www.ncbi.nlm.nih.gov/pubmed/31302628 http://dx.doi.org/10.1136/bjophthalmol-2018-313447

Ejemplares similares

HIGH-DOSE HIGH-FREQUENCY AFLIBERCEPT FOR RECALCITRANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
por: You, Qi Sheng, et al.
Publicado: (2018)

A Randomized, Controlled Trial of Treat-and-Extend vs. Pro Re Nata Regimen for Neovascular Age-Related Macular Degeneration
por: Jia, Huixun, et al.
Publicado: (2022)

Pro re nata versus fixed aflibercept regimen for neovascular age-related macular degeneration: a systematic review and meta-analysis
por: Victor, Andi Arus, et al.
Publicado: (2022)

Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat‐and‐extend compared with pro re nata in eyes with neovascular age‐related macular degeneration
por: Aurell, Sandra, et al.
Publicado: (2018)

Ten-year real-world outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration using pro re nata regimen
por: Hujanen, Pekko, et al.
Publicado: (2023)

Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab
por: Elwes, Flora, et al.
Publicado: (2018)

Quantifying the Separation Between the Retinal Pigment Epithelium and Bruch's Membrane using Optical Coherence Tomography in Patients with Inherited Macular Degeneration
por: Khan, Kamron N., et al.
Publicado: (2020)

Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients
por: Yamamoto, Akiko, et al.
Publicado: (2013)

One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial
por: Wang, Fenghua, et al.
Publicado: (2019)

Intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life
por: Inoue, Maiko, et al.
Publicado: (2014)

Treat-and-Extend vs. Pro Re Nata Regimen of Ranibizumab for Diabetic Macular Edema—A Two-Year Matched Comparative Study
por: Lai, Tso-Ting, et al.
Publicado: (2022)

Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment
por: Wecker, Thomas, et al.
Publicado: (2019)

Efficacy and safety of a new ranibizumab biosimilar CKD-701 using a pro re nata treatment regimen in neovascular age-related macular degeneration: A phase 3 randomized clinical trial
por: Yoon, Chang Ki, et al.
Publicado: (2022)

Quantitative optical coherence tomography angiography biomarkers for neovascular age-related macular degeneration in remission
por: Coscas, Florence, et al.
Publicado: (2018)

Histology of neovascular myopic macular degeneration
por: Jonas, Shefali B., et al.
Publicado: (2021)

Recurrence of neovascular age-related macular degeneration after cessation of treat and extend regimen
por: Hirata, Yuki, et al.
Publicado: (2022)

Pro Re Nata Use of Psychotropic Medications in Assisted Living
por: Carder, Paula, et al.
Publicado: (2020)

One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
por: Matsumoto, Hidetaka, et al.
Publicado: (2022)

Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
por: Matsumoto, Hidetaka, et al.
Publicado: (2023)

Real-world experience with pro re nata dosing of intravitreal dexamethasone implant for eyes with refractory diabetic macular edema
por: Rishi, Pukhraj, et al.
Publicado: (2020)

The Impact of Interval between Recurrence and Reinjection in Anti-VEGF Therapy for Diabetic Macular Edema in Pro Re Nata Regimen
por: Takamura, Yoshihiro, et al.
Publicado: (2021)

Neovascular age-related macular degeneration without exudative recurrence over 24 months after initial remission
por: Cho, Han Joo, et al.
Publicado: (2022)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

Pro Re Nata Prescription and Perception Difference between Doctors and Nurses
por: Oh, Se Hwa, et al.
Publicado: (2014)

Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study
por: Bilgic, Alper, et al.
Publicado: (2021)

Clinical outcome using a modified treat-and-extend protocol for neovascular age-related macular degeneration
por: Vofo, Brice Nguedia, et al.
Publicado: (2022)

Real-Life Efficacy of Bevacizumab Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion according to Pro Re Nata or Treat-and-Extend Regimen in Eyes with or without Epiretinal Membrane
por: Hamam, Moustafa, et al.
Publicado: (2022)

Radiation therapy for neovascular age-related macular degeneration
por: Petrarca, Robert, et al.
Publicado: (2011)

Experimental Models in Neovascular Age Related Macular Degeneration
por: Rastoin, Olivia, et al.
Publicado: (2020)

Pipeline therapies for neovascular age related macular degeneration
por: Arepalli, Sruthi, et al.
Publicado: (2021)

Association of neovascular age-related macular degeneration with migraine
por: Kuang, Tung-Mei, et al.
Publicado: (2022)

Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
por: Blazaki, Styliani, et al.
Publicado: (2023)

Patient Safety and Pro Re Nata Prescription and Administration: A Systematic Review
por: Vaismoradi, Mojtaba, et al.
Publicado: (2018)

Drusen characteristics of type 2 macular neovascularization in age-related macular degeneration
por: Ahmed, Daniel, et al.
Publicado: (2020)

Choroidal Modifications Preceding the Onset of Macular Neovascularization in Age-Related Macular Degeneration
por: Arrigo, Alessandro, et al.
Publicado: (2021)

Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
por: Ferro Desideri, Lorenzo, et al.
Publicado: (2023)

Visual and anatomical outcomes associated with treat-and-extend administration of intravitreal aflibercept for neovascular age-related macular degeneration
por: Soliman, Mohamed Kamel, et al.
Publicado: (2021)

Optical Coherence Tomography Angiography to Distinguish Changes of Choroidal Neovascularization after Anti-VEGF Therapy: Monthly Loading Dose versus Pro Re Nata Regimen
por: Miere, Alexandra, et al.
Publicado: (2018)

Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR
por: Freund, K. Bailey, et al.
Publicado: (2022)

Segmentation of macular neovascularization and leakage in fluorescein angiography images in neovascular age-related macular degeneration using deep learning
por: Holomcik, David, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fdmn048sop3d3sc4n923lnbs2q